Prostate Cancer / 2011 / Article / Tab 4

Clinical Study

Bevacizumab and Weekly Docetaxel in Patients with Metastatic Castrate-Resistant Prostate Cancer Previously Exposed to Docetaxel

Table 4

Number of patients experiencing the most frequent treatment-related adverse events.

Grade 1Grade 2Grade 3

Hematological
 Neutropenia19 (44.1%) 14 (32.5%) 8 (18.6%)
 Anemia20 (46.5%) 15 (34.8%) 6 (13.9%)
 Thrombocytopenia18 (41.8%) 12 (27.9%) 4 (9.3%)

Nonhematological
 Nausea/vomiting 12 (27.9%) 8 (18.6%) 0
 Diarrhea 9 (20.9%) 6 (13.9%) 0
 Constipation 13 (30.2) 11(25.5%) 0
 Nail changes 22 (51.1% ) 17 (39.5%) 2 (4.6%)
 Dry eye/tearing 26 (60.4%) 15 (34.8%) 0
 Myalgia/arthralgia 22 (51.1%) 14 (32.5%) 0
 Fatigue 21 (48.8%) 18 (41.8%) 2 (4.6%)
 Sensory neuropathy 16 (37.2%) 7 (16.2%) 0
 Peripheral edema 22 (51.1%) 8 (18.6%) 0
 Epistaxis 23 (53.4%) 7 (16.2%) 1 (2.3%)
 Dyspnea 12 (27.9%) 5 (11.6%) 0

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19.